Stereotactic Radiation to Decrease Pancreatic Secretions
Utilization of Stereotactic Radiation in Patients With Pancreatic Fistula to Decrease Pancreatic Secretions
1 other identifier
interventional
1
1 country
1
Brief Summary
Patients that have undergone pre-operative radiation for pancreatic carcinoma, that upon pathologic examination of the normal portion of the pancreatic gland that was in the radiation field showed acute and chronic changes in the pancreatic cells. The hypothesis for utilizing stereotactic radiation on pancreatic fistulae is that the treatment will decrease pancreatic secretions, thus decreasing autodigestion.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2012
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2012
CompletedFirst Submitted
Initial submission to the registry
August 1, 2012
CompletedFirst Posted
Study publicly available on registry
August 3, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2012
CompletedResults Posted
Study results publicly available
April 1, 2014
CompletedJune 10, 2022
February 1, 2014
4 months
August 1, 2012
February 14, 2014
June 8, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Decreased Secretions
Measurement of pancreatic panel, decreased Pancreatic Secretions
1 year
Study Arms (1)
Stereotactic Radiation
EXPERIMENTALTreatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery.
Interventions
Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery that could produce a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland.
Eligibility Criteria
You may qualify if:
- Pancreatic fistula
- Non-surgical candidate
You may not qualify if:
- Surgical candidate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Carolinas Medical Center
Charlotte, North Carolina, 28204, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- David Iannitti, MD
- Organization
- Carolinas Medical Center
Study Officials
- PRINCIPAL INVESTIGATOR
David Sindram, MD
Wake Forest University Health Sciences
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 1, 2012
First Posted
August 3, 2012
Study Start
July 1, 2012
Primary Completion
November 1, 2012
Study Completion
November 1, 2012
Last Updated
June 10, 2022
Results First Posted
April 1, 2014
Record last verified: 2014-02